Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Binu Krishnan (Trivandrum, India), Binu Krishnan, S. Priya. Diagnostic value of FeNO in COPD and asthma - COPD overlap syndrome. Eur Respir J 2016; 48: Suppl. 60, 1844

Member's Comments

No comment yet.

Related content which might interest you: Characterization of airway inflammation in patients with asthma COPD overlap syndrome using FeNO levels Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Using fractional exhaled nitric oxide level to differentiate asthma–COPD overlap syndrome from COPD Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018 Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)? Source: International Congress 2017 – Lung function testing in different patient categories Year: 2017 The influence of asthma and COPD exacerbation on exhaled mitric oxide (FENO) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004 The asthma–COPD overlap syndrome Source: Eur Respir Monogr 2015; 69: 85-95 Year: 2015 Temporal stability of feno measurement in COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Exhaled NO (FeNO) levels in patients with exacerbation of COPD and/or bronchiectasis Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Exhaled nitric oxide in diagnosis and management of respiratory diseases Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 Two sites of airway obstruction identified by post-bronchodilation change of exhaled nitric oxide in COPD patients Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Concomitant use of fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) as markers for predicting asthma exacerbation Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Differences between asthma–COPD overlap syndrome and adult-onset asthma Source: Eur Respir J, 49 (5) 1602383; 10.1183/13993003.02383-2016 Year: 2017 Diagnosing asthma and prognostic significance of eNO Source: Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management Year: 2005 Phenotypic characterization of asthma-COPD overlap syndrome: Comparison with asthma and COPD Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 Combination of elevated exhaled nitric oxide and serum eosinophil cationic protein identifies asthma patients at risk for exacerbation Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 Utility of FeNO in differentiating ACO and COPD Source: International Congress 2019 – Airway physiology Year: 2019 Characterization of allergic airway inflammation in patients with COPD using fractional exhaled nitric oxide levels Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 COPD and asthma overlap with bronchiectasis Source: Eur Respir Monogr 2018; 81: 167-185 Year: 2018 Usefulness of fractional exhaled nitric oxide (FeNO) for early diagnosis of asthma in patients with nonspecific respiratory symptoms Source: Annual Congress 2009 - From cough to sound analysis of breathing Year: 2009 Exhaled nitric oxide (FeNO), sputum analysis and asthma control score in children with mild to moderate asthma Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008